| 查看: 138 | 回复: 0 | |||
| 当前主题已经存档。 | |||
tiancai_erbao铁杆木虫 (小有名气)
|
[交流]
Laquinimod－－治疗多发性硬化的新型口服药（柳叶刀）
|
||
|
Laquinimod, a new oral drug for multiple sclerosis Authors of an Article conclude that the new drug laquinimod taken orally could be an effective treatment for multiple sclerosis (MS), can reduce MRI disease activity, and is well-tolerated in patients with the relapse-remitting form of the disease. Currently available drugs for the treatment of MS are all injectable, and thus the availability of an oral agent could be an advantage in terms of convenience for patients. Relapsing-remitting multiple sclerosis is an inflammatory demyelinating disease of the CNS that is presumed to have an autoimmune cause. In most patients, the disease is chronic and progresses over decades. Early stages are heralded by relapses of neurological dysfunction within the CNS associated with transient gadolinium-enhancing lesions on T1-weighted MRI that usually leave chronic non-enhancing T1 and T2 lesions in their wake. MRI measures of disease activity have been widely adopted to screen for effectiveness of new therapies in phase I and II clinical trials, although they do not serve as the sole determinant of efficacy in phase III trials. Approved immunomodulatory drugs for relapsing-remitting multiple sclerosis are all injectable and include interferon β-1a (which is given either subcutaneously or intramuscularly), interferon β-1b and glatiramer acetate (subcutaneous), and mitoxantrone and natalizumab (intravenous). The drugs reduce the numbers of clinical relapses and new inflammatory lesions (on MRI), and decrease short-term disability to varying degrees. Many patients would prefer oral drugs, and drug com panies are seeking to provide oral treatments for multiple sclerosis with safety and efficacy that are similar to those of available treatments. In today’s Lancet, Giancarlo Comi and colleagues2 report that a new oral drug, laquinimod at 0.6 mg daily, reduces new MRI lesions in relapsing-remitting multiple sclerosis. The mean cumulative number of T1 gadolinium-enhancing lesions per MRI scan done every 4 weeks from weeks 24 to 36 was 2.6 in the treatment group compared with 4.2 in the placebo group (absolute risk reduction 1.6, relative risk reduction 40%). Secondary MRI outcomes, including cumulative number of new T2 lesions and T1 hypointense lesions, also showed benefit. |
回复此楼» 猜你喜欢
一志愿天中医中药学专硕，希望有b区的老师可以考虑一下我
已经有1人回复
-
调剂
已经有3人回复
-
药理学论文润色/翻译怎么收费?
已经有161人回复
-
药学学硕326求调剂
已经有0人回复
-
26年博士申请
已经有20人回复
-
药理学、临床药学方向 调剂
已经有1人回复
-
求助 苯磷硫胺JP
已经有0人回复
-
100金币 阿莫西林克拉维酸钾片BP药典中提到的克拉维酸聚合物具体结构式是啥？
已经有2人回复
-
膳食补充剂合规性交流
已经有0人回复
-
一志愿浙大药学求调剂
已经有0人回复
-
高温高压反应求助
已经有4人回复
